Tocilizumab in Graves’ orbitopathy
2 February 2024
| Hetvi Bhatt
|
Oculoplastics, Orbit
|
Graves’ orbitopathy, Tocilizumab, corticosteroid
This prospective European study looks at the response to tocilizumab in corticosteroid-resistant disease. Tocilizumab (TCZ) is a monoclonal antibody that competitively inhibits IL-6 binding to its receptor. Unlike teprotumumab, the advantage of TCZ is that it is already used within...
